drugset / Trial / NCT01525082
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to evaluate the effectiveness and safety of a combination of capecitabine, temozolomide and bevacizumab in the treatment of advanced pancreatic neuroendocrine tumors.
Timeline
- Start
- 2012-12
- Primary completion
- 2018-01
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Temozolomide | Small molecule | — | Oral |